- Ivy Leaf Extract
-
- $10.00 / 1kg
-
2026-03-04
- CAS:14216-03-6
- Min. Order: 1kg
- Purity: Hederacoside C 3%
- Supply Ability: 10000
- Hederacoside C
-
- $65.00 / 50mg
-
2026-03-04
- CAS:14216-03-6
- Min. Order:
- Purity: 99.93%
- Supply Ability: 10g
- Hederacoside C
-
- $6.00 / 1KG
-
2025-09-25
- CAS:14216-03-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
|
| | Hederacoside C Basic information |
| | Hederacoside C Chemical Properties |
| Melting point | 222 °C (dec.)(lit.) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Inert atmosphere,2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly, Sonicated), Pyridine (Sparingly) | | form | Solid | | pka | 12.50±0.70(Predicted) | | color | White to Pale Beige | | BRN | 4229541 | | Stability: | Hygroscopic | | Major Application | food and beverages | | InChIKey | RYHDIBJJJRNDSX-MCGLQMIESA-N | | LogP | 4.520 (est) |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 22-24/25 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | F | 10-23 | | HS Code | 29389090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Hederacoside C Usage And Synthesis |
| Chemical Properties | White powder | | Uses | solubilizer, bio-availability enhancer in oral suspensions, capsules | | Uses | Hederacoside C is a Hedera helix leaf which has been used in botanical drug formulations to treat acute respiratory infection and bronchitis. Anti-myocardial. | | Definition | ChEBI: A triterpenoid saponin with hederagenin as the aglycone part. It has been isolated from the stem bark of Kalopanax pictus. | | Synthesis | Take dry manipulation ivy stems and leaves 500g, crushed, with 30% ethanol 4000mL, 2000mL at 80 successively heated reflux for two times, reflux time were 3 hours, 2 hours. Combine the two extracts, decompression recovery of solvent, get ivy crude extract. The crude extract of ivy was dissolved in 150 mL of water in an ultrasonic generator, and the aqueous solution was extracted with equal volumes of ether, ethyl acetate and n-butanol for three times, respectively. The three n-butanol extracts were combined, concentrated under reduced pressure to near dryness and dissolved in 80 mL of 95% ethanol. Gradually add ethyl acetate to the 95% ethanol solution under stirring until no more precipitate was produced, and then collect the precipitate by filtration after 2 hours of standing. The precipitate was dissolved with a small amount of methanol and eluted by column chromatography using silica gel as stationary phase and a mixture of chloroform:methanol equal to 65:35 as mobile phase. The eluent was collected, and the collected eluent containing ivyoside C was concentrated and freeze-dried to obtain ivyoside C1.0759 g, and the content of ivyoside C was 98.2% as detected by high performance liquid chromatography. | | in vivo | Hederacoside C (0.625, 1.25, 2.5 mg/kg, intraperitoneally injected for 7 consecutive days) can alleviate TNBS-induced enteritis[1].
Hederacoside C (5, 10, 50 mg/kg, intraperitoneally injected for 3 consecutive times for 8 h) can attenuate the breast lesions caused by Staphylococcus aureus[2].
| Animal Model: | TNBS-induced colitis in rat[1] | | Dosage: | 0.625, 1.25, 2.5 mg/kg | | Administration: | i.p. for 7 days | | Result: | Decreased the levels of inflammatory cytokines, including TNF-α, IL-6, IL-1β, CXCL-1, CXCL-2, and CXCL-5.
Reduced cell apoptosis in TNBS-induced colitis.
Reduced Bax/Bcl-2 ratio, cleaved caspase 3, and p53 protein levels in a dose-dependent manner.
|
|
| | Hederacoside C Preparation Products And Raw materials |
|